The proposed rule would allow plans to make broader use of prior authorization and step therapy for drugs—including drugs in protected classes—that are covered under Part D.
As part of the Trump administration’s blueprint to lower drug prices and reduce out-of-pocket spending for patients, CMS this week issued a proposed rule aimed at reducing the cost of Part D drugs.
Under the proposed rule, Part D sponsors would be allowed to exclude drugs from formulary if they represent only new formulations of existing single-source drugs or biologics, and they also are allowed to exclude drugs if their prices exceed a certain threshold over a specified look-back period. These provisions, says CMS, will allow plans to negotiate better prices for drugs, and could save the government $1.85 billion—and save enrollees $692 million in cost-sharing—by 2029.
Furthermore, the rule allows plans to make broader use of prior authorization and step therapy for drugs—including drugs in protected classes—that are covered under Part D.
CMS has already allowed step therapy for Part B drugs, which are physician-administered therapies (including biologics such as infliximab, rituximab, and other infused products). The newly announced proposed rule would create a similar policy for self-administered Part D drugs (including biologics such as pegfilgrastim, etanercept, and adalimumab).
Under the proposal, only new patients would be subject to step therapy for their Part D therapies, and step therapy requirements would have to be reviewed and approved by a plan’s pharmacy and therapeutics committee. Additional requirements stipulate that plans must continue to cover at least 2 drugs per class.
According to a CMS blog post authored by HHS Secretary Alex Azar and CMS Administrator Seema Verma, step therapy for Part D drugs could include a beneficiary starting treatment with a low-cost biosimilar before receiving a costlier biologic.
“Some say that allowing step therapy and prior authorization would restrict access to prescription drugs. However, these changes protect patient access, as the Part D program is embedded with strong patient protections,” wrote Azar and Verma. “CMS reviews plan formularies to guard against discriminatory practices, and the agency has in place an expedited appeals process for cases in which a physician recommends an exception to prior authorization or other forms of management.”
Provider groups were quick to respond to CMS’ proposal; the Community Oncology Alliance (COA) issued a statement saying that the push to use step therapy is driven by financial interests, not by the best interests of those receiving medical treatment.
“Patients are left at the whim of insurance and pharmacy benefit manager middlemen who are more concerned with their profit margins than patient outcomes, side effects, and wellbeing,” COA’s president, Jeff Vacirca, MD, FACP, said in a statement. “Treatment decisions are made by nameless and faceless corporate bureaucrats who are often not board certified in the diseases they are making coverage decisions over,” he added.
Other provisions of the proposal include requiring explanations of benefits to include drug pricing information, requiring plans to adopt real-time benefit management tools that can inform prescribers when lower-cost therapies are available, prohibiting so-called gag clauses in pharmacy contracts, and redefining baseline payments to pharmacies as a means to reduce cost-sharing and out-of-pocket costs for beneficiaries.
CMS will accept comments on the proposed rule until January 25, 2019.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.
2 Commerce Drive
Cranbury, NJ 08512